Geron Initiates Clinical Trial of Human Embryonic Stem Cell-Based Therapy in 
Patients with Spinal Cord Injury
October 11, 2010 7:30 AM ET

Geron Corporation GERN today announced the enrollment of the first patient in 
the company's clinical trial of human embryonic stem cell (hESC)-derived 
oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase 
I study is to assess the safety and tolerability of GRNOPC1 in patients with 
"complete" American Spinal Injury Association (ASIA) Impairment Scale grade A 
thoracic spinal cord injuries. Participants in the study must be newly injured 
and receive GRNOPC1 within 14 days of the injury. 

The patient was enrolled at Shepherd Center, a 132-bed spinal cord and brain 
injury rehabilitation hospital and clinical research center in Atlanta, GA. 
Shepherd Center is one of seven potential sites in the United States that may 
enroll patients in the clinical trial. 

"Initiating the GRNOPC1 clinical trial is a milestone for the field of human 
embryonic stem cell-based therapies," said Thomas B. Okarma, Ph.D., M.D., 
Geron's president and CEO. "When we started working with hESCs in 1999, many 
predicted that it would be a number of decades before a cell therapy would be 
approved for human clinical trials. This accomplishment results from extensive 
research and development and a succession of inventive steps to enable 
production of cGMP master cell banks, scalable manufacture of differentiated 
cell product, and preclinical studies in vitro and in animal models of spinal 
cord injury, leading to concurrence by the FDA to initiate the clinical trial." 

"We are pleased to have our patients participating in this exciting research," 
said Donald Peck Leslie, M.D., medical director, Shepherd Center. "Our medical 
staff will evaluate the patients' progress as part of this study. We look 
forward to participating in clinical trials that may help people with spinal 
cord injury." 

David Apple, M.D., Shepherd Center's medical director emeritus and principal 
investigator of the trial at Shepherd Center, said, "This clinical trial 
represents another step forward in Shepherd Center's involvement in an attempt 
to find a cure for paralysis in people with spinal cord injury. Shepherd Center 
is an ideal place to conduct this study because of our clinical expertise and 
the volume of patients referred here for rehabilitation care." 

In addition to Shepherd Center, Northwestern Medicine in Chicago, IL is also 
open for patient enrollment. As additional trial sites come online and are 
ready to enroll patients, they will be listed on the Patient Information pages 
of Geron's website at www.geron.com/patients/clinicaltrials/hESC.aspx and on 
the NIH clinical trials registry, ClinicalTrials.gov, at 
clinicaltrials.gov/ct2/show/NCT01217008?term=GRNOPC1&rank=1. 

Further information on the criteria for patient eligibility for the study is 
also available on ClinicalTrials.gov. 

About Spinal Cord Injury

Spinal Cord Injury (SCI) is caused by trauma to the spinal cord that results in 
a loss of such functions as locomotion, sensation or bowel/bladder control. A 
traumatic blow to the spine can fracture or dislocate vertebrae that may cause 
bone fragments or disc material to injure the nerve fibers and damage the glial 
cells that insulate the nerve fibers in the spinal cord. Most human SCIs are 
contusions (bruises) to the cord, rather than a severance of the nerve fibers. 
Every year approximately 12,000 people in the U.S. sustain spinal cord 
injuries. The most common causes are automobile accidents, falls, gunshot 
wounds and sports injuries. 

About GRNOPC1

GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have 
demonstrated remyelinating and nerve growth stimulating properties leading to 
restoration of function in animal models of acute spinal cord injury. 
Preclinical studies showed that administration of GRNOPC1 significantly 
improved locomotor activity and kinematic scores of animals with spinal cord 
injuries when injected seven days after the injury. Histological examination of 
the injured spinal cords treated with GRNOPC1 showed improved axon survival and 
extensive remyelination surrounding the rat axons. For more information about 
GRNOPC1, visit www.geron.com/GRNOPC1Trial/. 

About Shepherd Center

Shepherd Center is a private, not-for-profit rehabilitation hospital 
specializing in medical treatment, research and rehabilitation for people with 
spinal cord injury and disease, brain injury, multiple sclerosis, chronic pain 
and other neuromuscular conditions. Each year Shepherd Center admits more than 
940 inpatients and more than 530 day program patients. Its staff also treats 
about 6,000 people on an outpatient basis annually. For more information, visit 
Shepherd Center online at shepherd.org. 

About Geron

Geron is developing first-in-class biopharmaceuticals for the treatment of 
cancer and chronic degenerative diseases, including spinal cord injury, heart 
failure and diabetes. The company is advancing an anti-cancer drug and a cancer 
vaccine that target the enzyme telomerase through multiple clinical trials. For 
more information, visit www.geron.com. 

This news release may contain forward-looking statements made pursuant to the 
"safe harbor" provisions of the Private Securities Litigation Reform Act of 
1995. Investors are cautioned that statements in this press release regarding 
potential applications of Geron's human embryonic stem cell technology 
constitute forward-looking statements that involve risks and uncertainties, 
including, without limitation, risks inherent in the development and 
commercialization of potential products, uncertainty of clinical trial results 
or regulatory approvals or clearances, need for future capital, dependence upon 
collaborators and protection of our intellectual property rights. Actual 
results may differ materially from the results anticipated in these 
forward-looking statements. Additional information on potential factors that 
could affect our results and other risks and uncertainties are detailed from 
time to time in Geron's periodic reports, including the quarterly report on 
Form 10-Q for the quarter ended June 30, 2010. 




Geron:
Anna Krassowska, Ph.D., 650-473-7765
Investor and Media Relations
[email protected]
or
Shepherd Center:
Jane Sanders, 404-350-7707
Public Relations
[email protected]

Copyright 2010 Business Wire

Attachment: CT?id=bwnews&sty=20101011005329r1&sid=msn02&distro=nx
Description: Binary data

Reply via email to